Blog

Dekel Agri-Vision Plc (LSE:DKL) has released its Q3 2025 production update, showing a mixed operational performance across its palm oil and cashew businesses in Côte d’Ivoire.

The Palm Oil Operation recorded a sharp decline in crude palm oil (CPO) production and sales, primarily due to reduced Fresh Fruit Bunch volumes. Higher CPO and palm kernel oil prices partially offset the financial impact of lower output.

In contrast, the Cashew Operation delivered a standout performance, with raw cashew nut processing surging by 354% year-on-year and cashew sales increasing nearly sixfold. This growth was driven by the installation of new processing equipment and improved operational efficiency. Dekel Agri-Vision plans to continue scaling its cashew processing capacity by the end of 2025 and expects palm oil production to recover as the high season approaches.

While the company shows operational progress in cashews, its financial outlook remains pressured by high leverage, ongoing losses, and bearish technical indicators, signaling potential headwinds in the near term.

About Dekel Agri-Vision Plc

Dekel Agri-Vision is a multi-commodity agriculture company operating in West Africa. Its key assets in Côte d’Ivoire include a fully operational palm oil project in Ayenouan, which processes fruit from local smallholders at a 60,000tpa crude palm oil mill, and a cashew processing facility in Tiebissou that is currently ramping up production. The company aims to build a diversified agribusiness platform through strategic scaling and operational expansion.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Genflow Biosciences Plc (LSE:GENF) has successfully completed a second administration of its proprietary SIRT6-centenarian gene therapy in a clinical trial involving elderly dogs. The treatment was well tolerated, with no safety concerns observed, underscoring the strong safety profile of the company’s gene therapy platform.

This achievement marks an important step in Genflow’s strategy to expand its innovative genetic longevity platform beyond human therapeutics and into the growing global animal health market. The company intends to build on this progress by advancing its animal health initiatives and pursuing strategic partnerships to accelerate commercialization opportunities.

About Genflow Biosciences Plc

Founded in 2020 and headquartered in the UK with R&D operations in Belgium, Genflow Biosciences is a biotechnology company focused on developing gene therapies to slow the aging process. Its lead candidate, GF-1002, uses a centenarian variant of the SIRT6 gene, which has shown promising results in preclinical research. The company aims to promote healthier, longer lives and is also exploring therapeutic applications for chronic liver disease.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Sareum Holdings PLC (LSE:SAR) has announced the discontinuation of its 16-week GLP preclinical toxicology study for SDC-1801 after safety issues were identified in control-group animals that received only an inactive dosing solution. The company has launched an investigation to determine the root cause of these findings and intends to restart the study with a new research provider. Sareum expects to complete the revised program using its existing cash resources.

While the development marks a setback, Sareum highlighted that no safety concerns were observed in earlier Phase 1 trials. The company remains committed to advancing SDC-1801 into Phase 2 clinical development for psoriasis once the toxicology study is successfully completed.

Despite promising scientific progress, Sareum continues to face significant financial headwinds, including the absence of revenue and ongoing losses. Although technical indicators suggest some short-term strength and recent strategic updates offer optimism, valuation challenges remain due to negative earnings.

About Sareum Holdings PLC

Sareum Holdings is a clinical-stage biotechnology company headquartered in Cambridge, UK. It focuses on the development of next-generation kinase inhibitors targeting autoimmune diseases and cancer, with a goal of advancing innovative therapies into clinical stages and eventual commercialization.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

GenIP Plc (LSE:GNIP) has introduced a new product, ‘Invention Validator’, designed to assess user perception and market readiness for technological innovations. Currently in its pilot phase, the service is initially being applied within the agriculture sector but is expected to expand to additional industries over time.

The Invention Validator integrates GenIP’s existing Invention Evaluator report with targeted market and validation research, providing clients with strategic recommendations to guide commercialization decisions. By leveraging AI-driven analysis and user feedback, the product aims to replace slow, traditional market studies and reduce reliance on uncertain assumptions, ultimately delivering faster, more actionable insights.

This launch represents a key milestone in GenIP’s strategy to become a deeply embedded partner in clients’ commercialization processes. The company anticipates the service could help generate recurring revenue streams and support long-term growth.

About GenIP Plc

GenIP Plc is a technology consultancy specializing in Generative Artificial Intelligence (GenAI) solutions that help research organizations and corporations bring innovations to market. The company operates through two main divisions: the Invention Intelligence Product Suite, which offers AI-powered market intelligence, and Talent and Executive Search Services, connecting innovation-focused businesses with leadership equipped for commercialization. GenIP’s strategy centers on expanding its global footprint in GenAI analytics through organic growth, deeper service integration, and targeted acquisitions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Enwell Energy plc (LSE:ENW) has reported that the suspension of its MEX-GOL, SV, and VAS production licenses in Ukraine remains in place due to sanctions imposed on its ultimate beneficial owners. In response, the company is pursuing legal and arbitration proceedings aimed at overturning the suspensions and securing compensation for damages. At the same time, Enwell continues to prioritize employee safety and maintain a strong financial position, with cash reserves of approximately $99.9 million.

While technical indicators point to a bearish trend in the short term, Enwell’s solid financial performance and attractive valuation provide underlying support. Its low P/E ratio may signal potential undervaluation, though market sentiment remains cautious.

About Enwell Energy plc

Enwell Energy is an oil and gas exploration and production company listed on the AIM market. Its operations are centered in Ukraine, focusing on the development and production of gas and condensate fields. The company’s core assets include the Mekhediviska-Golotvshinska (MEX-GOL), Svyrydivske (SV), and Vasyschevskoye (VAS) fields.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Reabold Resources plc (LSE:RBD) has increased its ownership in LNEnergy Limited by 1.2% through a rights issue, raising its total holding to approximately 47.4%. LNEnergy, through its subsidiary, maintains a significant interest in the Colle Santo gas field in Italy.

In addition to increasing its stake, Reabold has entered into an agreement with Beacon Energy PLC to sell part of its interest in LNEnergy. The first phase of the transaction is expected to close in November 2025. The move aligns with Reabold’s broader strategy to prioritize strategic gas projects that support European energy security.

About Reabold Resources plc

Reabold Resources is an investment-focused company with a diverse portfolio of oil and gas exploration, appraisal, and development projects. Its strategy centers on low-risk, near-term opportunities with strong value growth potential and a defined monetization plan. The company has a track record of returning proceeds to shareholders and reinvesting in growth assets, as seen in its recent sale of the undeveloped Victory gas field to Shell.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

JTC PLC (LSE:JTC) has announced an extension to the deadline for Warburg Pincus LLC to decide whether it will make a formal acquisition offer for the company. Warburg Pincus, through its managed private equity funds, previously submitted a preliminary and conditional non-binding proposal to acquire JTC’s entire issued share capital.

The new deadline for Warburg Pincus to either announce a firm intention to make an offer or confirm that it will not proceed is now set for 24 October 2025. This extension provides additional time for discussions between the parties. However, JTC has emphasized that there is no guarantee the talks will lead to a formal bid.

JTC’s outlook remains supported by strong technical momentum, positive sentiment from recent earnings discussions, and ongoing revenue growth. Strategic acquisitions further strengthen its position. Even so, profitability concerns, a high P/E ratio, and net losses suggest investors should remain cautious.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

AFC Energy plc (LSE:AFC) has released an update to shareholders following the outcome of its Annual General Meeting. Resolution 8, which concerned the 2024 remuneration report, was approved with 77.09% of votes in favor. Although the resolution passed, the company recognized the level of minority opposition and has since engaged with major shareholders to address their concerns. AFC Energy reaffirmed that the resolution aligns with its goal of driving long-term shareholder value.

In addition, the company announced a change to its broker lineup. RBC Europe Limited has stepped down as Joint Broker, while Zeus and Peel Hunt will continue in their existing roles.

AFC Energy continues to face notable financial headwinds, including profitability and cash flow challenges. Technical analysis indicates a bearish trend, while its valuation remains under pressure due to a negative P/E ratio and the absence of a dividend, contributing to a weak overall outlook.

About AFC Energy plc

AFC Energy is a UK-based provider of hydrogen energy solutions, specializing in clean electricity generation for both on-grid and off-grid applications. Its core technology is centered on fuel cells, which are used in electric vehicle charging, temporary power systems, and off-grid energy solutions. The company is also advancing ammonia cracking technology for distributed hydrogen production and is targeting high-emission industries such as mining, cement, and heavy engineering, as well as emerging opportunities in maritime, data centers, and rail sectors.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Aptamer Group plc (LSE:APTA) has announced that it will release its full-year financial results for the period ending 30 June 2025 on 14 October 2025. Alongside the results, the company will hold an online analyst briefing and an investor presentation, offering stakeholders the opportunity to hear directly from the leadership team about the company’s financial performance and strategic priorities.

The update comes as Aptamer Group navigates a challenging financial landscape, marked by significant funding pressures and weak technical indicators. Nonetheless, recent corporate developments and strategic partnerships provide a degree of optimism for its future growth trajectory. Ongoing concerns remain around its reliance on debt and lack of profitability.

About Aptamer Group plc

Aptamer Group is a life sciences company specializing in the development of next-generation synthetic binders. Its innovative platform aims to deliver advanced solutions that enhance research and development capabilities across the life science sector.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Nuformix plc (LSE:NFX) has announced the appointment of Kreston Reeves Audit LLP as its new auditor. The move follows the restructuring of its former auditor, Kreston Reeves LLP, and remains subject to shareholder approval at the company’s upcoming Annual General Meeting.

This appointment is part of Nuformix’s efforts to strengthen financial governance and oversight as it advances its strategic objectives in the pharmaceutical development space. By reinforcing its auditing framework, the company aims to bolster operational efficiency and enhance stakeholder confidence during a period of ongoing transition.

Despite recent positive technical signals and some encouraging corporate developments, Nuformix continues to face significant financial hurdles, including the absence of revenue and sustained losses. These challenges weigh heavily on its valuation, underscoring the importance of careful financial management moving forward.

About Nuformix plc

Nuformix is a pharmaceutical development company focused on repurposing drugs to address unmet medical needs, particularly in fibrosis and oncology. Its core expertise lies in discovering and developing novel drug forms with improved physical properties, offering new possibilities for dosage, delivery, and formulation. The company’s pipeline of preclinical assets presents opportunities for early licensing and potential value creation in the biopharmaceutical market.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.